TOMIVOSERTIB
Tomivosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against MAP kinase-interacting serine/threonine-protein kinase 2 and MAP kinase-interacting serine/threonine-protein kinase 1. In addition, it is known to target serine/threonine-protein kinase 17A and dual specificity protein kinase CLK4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TOMIVOSERTIB |
| INN | tomivosertib |
| Description | Tomivosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against MAP kinase-interacting serine/threonine-protein kinase 2 and MAP kinase-interacting serine/threonine-protein kinase 1. In addition, it is known to target serine/threonine-protein kinase 17A and dual specificity protein kinase CLK4. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1849590-01-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4073443 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | U2H19X4WBV (ChemIDplus, GSRS) |
Target
Agency Approved
MKNK2
MKNK2
MKNK1
MKNK1
Organism
Homo sapiens
Gene name
MKNK2
Gene synonyms
GPRK7, MNK2
NCBI Gene ID
Protein name
MAP kinase-interacting serine/threonine-protein kinase 2
Protein synonyms
G protein-coupled receptor kinase 7, MAP kinase interacting serine/threonine kinase 2, MAP kinase signal-integrating kinase 2, MAPK signal-integrating kinase 2, Mnk2
Uniprot ID
Mouse ortholog
Mknk2 (17347)
MAP kinase-interacting serine/threonine-protein kinase 2 (Q9D893)
Alternate
STK17A
STK17A
CLK4
CLK4
Organism
Homo sapiens
Gene name
STK17A
Gene synonyms
DRAK1
NCBI Gene ID
Protein name
serine/threonine-protein kinase 17A
Protein synonyms
DAP kinase-related apoptosis-inducing protein kinase 1, death-associated protein kinase-related 1, serine/threonine kinase 17a (apoptosis-inducing)
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 234 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use